These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Current diagnosis and treatment of chronic lymphocytic leukaemia]. Cramer P; von Tresckow J; Eichhorst B; Hallek M Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549 [TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613 [TBL] [Abstract][Full Text] [Related]
11. Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL. O'Brien SM Clin Adv Hematol Oncol; 2021 Oct; 19(10):636-638. PubMed ID: 34637429 [No Abstract] [Full Text] [Related]
12. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601 [TBL] [Abstract][Full Text] [Related]
13. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut. Huber H; Tausch E; Schneider C; Edenhofer S; von Tresckow J; Robrecht S; Giza A; Zhang C; Fürstenau M; Dreger P; Ritgen M; Illmer T; Illert AL; Dürig J; Böttcher S; Niemann CU; Kneba M; Al-Sawaf O; Kreuzer KA; Fink AM; Fischer K; Döhner H; Hallek M; Eichhorst B; Stilgenbauer S Blood; 2023 Sep; 142(11):961-972. PubMed ID: 37363867 [TBL] [Abstract][Full Text] [Related]
14. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study. Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin MD; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CU; Kater AP J Clin Oncol; 2023 Jul; 41(21):3689-3699. PubMed ID: 37279408 [TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes in Patients with Multi-Hit Brieghel C; Aarup K; Torp MH; Andersen MA; Yde CW; Tian X; Wiestner A; Ahn IE; Niemann CU Clin Cancer Res; 2021 Aug; 27(16):4531-4538. PubMed ID: 33963002 [TBL] [Abstract][Full Text] [Related]
16. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). Abrisqueta P; Loscertales J; Terol MJ; Ramírez Payer Á; Ortiz M; Pérez I; Cuellar-García C; Fernández de la Mata M; Rodríguez A; Lario A; Delgado J; Godoy A; Arguiñano Pérez JM; Berruezo MJ; Oliveira A; Hernández-Rivas JÁ; García Malo MD; Medina Á; García Martin P; Osorio S; Baltasar P; Fernández-Zarzoso M; Marco F; Vidal Manceñido MJ; Smucler Simonovich A; López Rubio M; Jarque I; Suarez A; Fernández Álvarez R; Lancharro Anchel A; Ríos E; Losada Castillo MDC; Pérez Persona E; García Muñoz R; Ramos R; Yáñez L; Bello JL; Loriente C; Acha D; Villanueva M Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e985-e999. PubMed ID: 34511320 [TBL] [Abstract][Full Text] [Related]
17. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Burger JA; Robak T; Demirkan F; Bairey O; Moreno C; Simpson D; Munir T; Stevens DA; Dai S; Cheung LWK; Kwei K; Lal I; Hsu E; Kipps TJ; Tedeschi A Leuk Lymphoma; 2022 Jun; 63(6):1375-1386. PubMed ID: 35014928 [TBL] [Abstract][Full Text] [Related]
18. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. Vitale C; Salvetti C; Griggio V; Porrazzo M; Schiattone L; Zamprogna G; Visentin A; Vassallo F; Cassin R; Rigolin GM; Murru R; Laurenti L; Rivela P; Marchetti M; Pennese E; Gentile M; Boccellato E; Perutelli F; Montalbano MC; De Paoli L; Reda G; Orsucci L; Trentin L; Cuneo A; Tedeschi A; Scarfò L; Gaidano G; Mauro FR; Foà R; Boccadoro M; Coscia M Blood; 2021 Jun; 137(25):3507-3517. PubMed ID: 33651883 [TBL] [Abstract][Full Text] [Related]
19. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? Suzumiya J; Takizawa J Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666 [TBL] [Abstract][Full Text] [Related]
20. Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis. Molica S; Giannarelli D; Montserrat E Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):216-223. PubMed ID: 33199185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]